The Opioid Crisis Is Driven by Demand, Not Just Supply

—

By Lynn Webster MD

Even as doctors have slashed opioid prescriptions, opioid use and overdose have not gone away. They have changed form, from diverted pills to heroin, illicit fentanyl, and polysubstance use. That shift should force us to ask a hard question: why did demand persist when the legal supply of prescription opioids fell?

The standard narrative treats pharmacology as the primary engine: opioids are powerful, rewarding, dependence-producing drugs, so widespread availability created widespread addiction. There is truth in that account. Supply matters, especially with ultra-potent synthetics capable of killing in tiny quantities. Fentanyl has made drug use far more lethal, especially for people with low tolerance or those who unknowingly consume it in counterfeit pills or adulterated supplies. But pharmacology alone cannot explain why so many Americans seek these drugs or why some communities are devastated while others are spared.

Bad narratives produce bad policy. If we define the opioid crisis mainly as a problem of too many prescriptions, then the logical response is to cut prescribing. That is what happened. Chastened by clinical guidelines, prescription-monitoring programs, legal fears, and changing medical norms, clinicians dramatically reduced opioid prescribing. Yet deaths did not fall as expected.

This disconnect should have amended the belief that prescribing alone explained the crisis. Instead, policy often doubled down. The result was predictable: when the legitimate supply contracted while treatment, pain care, mental health support, and social services failed to expand, demand did not disappear. It migrated.

Pill supplies may shrink, but pain, dependence, trauma, isolation, and despair remain. People who were already dependent, seeking relief, or living inside unstable environments did not suddenly become safe because prescriptions became harder to obtain. Some turned to heroin because it was cheaper and more available. Later, many were exposed to fentanyl—sometimes knowingly, but often not.

By 2015, heroin had become the first opioid used by 33.3% of new users, up from 8.7% in 2005. During the same period, initiation with misused prescription opioids declined sharply: oxycodone fell from more than 42% to 24.1%, and hydrocodone fell from more than 42% to 27.8%.

That pattern demonstrates that the same need for relief or reward was increasingly met by a more dangerous product. The lesson is that supply changed in response to demand. If heroin was lethal, fentanyl made the marketplace even less forgiving.

But fentanyl is not the whole story either. It is the accelerant, not the entire fire. Pharmacology explains why fentanyl kills efficiently; it does not explain why so many Americans are positioned in its path. The world’s illicit fentanyl would sit unsold if there were not a population living with unresolved pain, untreated mental illness, job loss, housing instability, trauma, stigma, and social disconnection. Drug misuse is about more than the substance, because behavior happens inside systems.

Similarly, the opioid crisis is not a monolith but a collection of overlapping sub-epidemics shaped by place, race, poverty, disability, labor conditions, prescribing norms, criminal justice practices, and access to care. Different communities face different risk environments that include far more than drug supply.

A risk environment includes whether a person has stable housing, transportation to treatment, a clinician willing to help, insurance coverage, trusted relationships, a safe place to recover, and a community that does not treat addiction as a moral failure. More than a feeling, stigma is built into treatment rules, prescribing systems, criminalization, and public attitudes.

This does not absolve pharmaceutical companies, pill mills, or reckless prescribers. To repeat, supply mattered as did unethical marketing and callous prescribing practices that caused harm. But the complex crisis cannot be explained by the single villain of supply. The supply-focused narrative became toxic when it drowned out discussion of deeper causes and measured success by fewer prescriptions rather than fewer deaths, less suffering, or greater well-being.

Short-term measures cannot address these deeper causes. Enforcement alone cannot combat the illicit market: fentanyl seizures, precursor controls, and cartel disruption may save lives in the short term, but they cannot treat despair, stabilize housing, repair fractured communities, or provide compassionate care for people with pain or addiction.

Prevention must encompass far more than prescribing restrictions; its success should be  measured by well-being, not driven by fear. A new approach must begin upstream, replacing punitive measures with trauma-responsive, multigenerational, equity-driven support that stabilizes families before a crisis hits. True systemic prevention builds an interconnected ecosystem, encompassing:

• Immediate harm reductionand access to evidence-based addiction treatment to keep people alive today.
•  Compassionate medical infrastructure that integrates humane pain management and proactive mental health care so patients are never driven to illicit markets out of medical desperation.
• Structural stabilization that secures the basics—like safe housing and meaningful employment—allowing individuals to build a life worth staying present for.

A vital pillar of this ecosystem is family support to break the cycle of multigenerational trauma. By providing at-risk families a path to access mental health resources, economic security, and parental support, homes can become safer and children more resilient before substance use can take hold. Ultimately, these measures are about social reintegration and restoring human dignity.

To do otherwise will only reproduce another crisis. The next potent drug supply will always find a market in a society that leaves too many people unprotected, untreated, and unseen. Better outcomes begin with better explanations. The opioid crisis did not emerge simply from supply. It emerged from the toxic synergy between availability and vulnerability. Until we confront both, we will keep dousing single flare-ups only to watch the wildfire ignite somewhere else.

Change the Narrative

The hyper-fixation on supply over demand is just one of many toxic narratives driving our current policy failures. In their new book, Deconstructing Toxic Narratives, Lynn R. Webster, MD, and Sarah Eichberg, PhD, outline a compassionate, systemic roadmap to truly heal our communities.

***

Lynn R. Webster, M.D. is one of the world’s leading authorities on pain management, addiction medicine, and the complex interplay between public policy, misinformation, and human suffering. Board-certified in Anesthesiology, Pain Medicine and Addiction Medicine, and past president of the American Academy of Pain Medicine (AAPM), he is the author of The Painful Truth: What Chronic Pain Is Really Like and Why It Matters to Each of Us and co-producer of the video documentary, “The Painful Truth,” which has aired on Public Broadcasting stations throughout the United States. He is co-author of the new book Deconstructing Toxic Narratives: Data, Disparities, and a New Path Forward in the Opioid Crisis (May 28, 2026).  Learn more at lynnwebstermd.com